Figure 7: MC TNFRSF14 is sufficient for OVA-induced asthma pathology.
(a) Changes in RL induced by aerosolized methacholine, (b) numbers of leukocytes in BAL fluid, (c,d) levels of plasma OVA-specific IgG1 (c) and IgE (d), (e) lung collagen and (f) numbers of engrafted eYFP+ mast cells in the lung, 24 h after the ninth OVA (or PBS) challenge in Tnfrsf14+/+ or Tnfrsf14−/− mice engrafted with Mcpt5-eYFP BMCMCs (Mcpt5-eYFP BMCMCs→Tnfrsf14+/+ and Mcpt5-eYFP BMCMCs→Tnfrsf14−/−). Three-to-five female mice per group were used as indicated. Results are pooled from two independent experiments, each of which gave similar results. (g) Lung sections stained with 4,6-diamidino-2-phenylindole and anti-YFP Ab, demonstrating engrafted lung MCs (eYFP+ cells, indicated by red colour) in Tnfrsf14+/+ or Tnfrsf14−/− mice engrafted with Mcpt5-eYFP BMCMCs (insets show images of representative eYFP+ MCs). Scale bar, 50 μm. The data in a–f (shown as mean+or±s.e.m.) were assessed for statistical significance using a two-tailed Student’s t-test or a two-way analysis of variance (ANOVA) test. Asterisks indicate statistical significance of differences between PBS-treated and corresponding Ag-treated groups. *P<0.05; **P<0.01; ***P<0.001.
